Venture dollars for Indiana life sciences companies are still few, but the flow of deals is picking up. Nine Hoosier companies
scored investments totaling $10.4 million during the first six months of the year.
Marion County survey finds 80 percent of respondents in debt to local hospitals, with about half saying they were never informed
about the availability
of charity care or payment plans.
With the first baby boomers set to turn 65 in six months, investments in senior housing are heating up. A group of Indianapolis-area
professionals—including Mark Waterfill (left) and Tony Schantz—have banded together to launch three senior housing
projects around the state, spending $49 million and looking
to do more.
Investors are focused on whether Eli Lilly and Co. can continue dividend payments when patent expirations hit in the new few
years and whether the company's drug development pipeline can replace lost revenue.
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months
ended June 30,
even after paying $27 million in severance to laid off employees.
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company
developing an enzyme-replacement therapy for disorders of the pancreas.
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
Indiana and other states face a struggle as they grapple with putting the health care changes into place in a relatively short
span of time while they also contend with the economic downtown and strained state budgets.
Clarian Health is launching its own health insurance plan, the boldest of several initiatives at Indianapolis hospitals to
bypass health insurers and provide health benefits directly to employers.
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115
cuts will be made this month, and the remainder by the end of the year.
Nearly four months after President Barack Obama signed a health reform bill into law, businesses are still grappling with its
impact on the health benefits they offer their employees.
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the
end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling
drugs.
Biomet could add about 280 jobs with the $26 million project, which would lead to some manufacturing being transferred from
New Jersey.
The Logansport State Hospital will have 355 workers laid off and 80 vacant positions eliminated under the plan, while 106
people will lose jobs at the Richmond State Hospital.
Eli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit
from a Lilly drug.
David Hartley pulled $85,000 from his savings six years ago to buy Home Health Depot Inc. Nearly six years later, Hartley
has reinvented the Indianapolis-based home medical equipment supplier, growing from a single office in Greenwood to 12 locations
in Indiana and Illinois—and increasing annual revenue from $300,000 to more than $6.7 million.
Unemployment in Indiana has moderated slightly, but more than 313,000 Hoosiers remain out of work. And with attempts to extend
benefits for the jobless stalled in Congress, it’s likely more people will struggle to pay medical bills.
Baldwin & Lyons Inc. provides property-and-casualty insurance for various industries, including trucking.
Dr. Bill Tierney will replace Dr. Tom Inui on Oct. 1 at helm of Indianapolis-based medical research organization.
